Marshall SF, Clarke CA, Deapen D, DeLellis Henderson K, Largent J, Neuhausen SL, Reynolds P, Ursin G, Horn-Ross PL, Stram DO, Templeman C, Bernstein L: Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res. 2010, 12: R4-10.1186/bcr2467.
Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007, 356: 1670-1674. 10.1056/NEJMsr070105.
Canfell K, Banks E, Moa A, Beral V: Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust. 2008, 188: 641-644.
Kumle M: Declining breast cancer incidence and decreased HRT use. Lancet. 2008, 372: 608-610. 10.1016/S0140-6736(08)61255-6.
Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.
Medicines and Healthcare Products Regulatory Agency: UK Public Assessment Report. Hormone-replacement therapy: safety update. 2007, London: Medicines and Healthcare Products Regulatory Agency, [http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con2032228.pdf]
Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 1997, 350: 1047-1059. 10.1016/S0140-6736(97)08233-0.
Million Women Study Collaborators: Breast cancer and hormone replacement therapy in the Million Women Study. Lancet. 2003, 362: 419-427. 10.1016/S0140-6736(03)14065-2.
Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G, WHI Investigators: Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009, 360: 573-587. 10.1056/NEJMoa0807684.
Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, Hollenbeck AR, Lacey JV: Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Cohort Study. Cancer Epidemiol Biomarkers Prev. 2008, 17: 3150-3160. 10.1158/1055-9965.EPI-08-0435.
Stahlberg C, Pedersen AT, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Møller S, Rank F, Ottesen B, Lynge E: Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer. 2004, 91: 644-650.
Austin DF, Roe FJ: The decreasing incidence of endometrial cancer: public health implications. Am J Public Health. 1982, 72: 65-68. 10.2105/AJPH.72.1.65.
Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R: Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000, 321: 323-329. 10.1136/bmj.321.7257.323.
Banks E, Canfell K: Invited commentary: hormone therapy risks and benefits--the Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol. 2009, 170: 24-28. 10.1093/aje/kwp113.
Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE: Benefits and risks of postmenopausal hormone therapy when initiated soon after then menopause. Am J Epidemiol. 2009, 170: 12-23. 10.1093/aje/kwp115.